Systematic review and meta‐analysis of potential pleiotropic effects of sevelamer in chronic kidney disease: Beyond phosphate control-Reference-Cited by-同舟云学术

Systematic review and meta‐analysis of potential pleiotropic effects of sevelamer in chronic kidney disease: Beyond phosphate control

Published:2021-12-27 Issue: Volume: Page:
ISSN:1320-5358
Container-title:Nephrology
language:en
Short-container-title:Nephrology

Author:

Basutkar Roopa Satyanarayan¹,Varghese Resia¹,Mathew Nina Kallanthanath¹,Sankar Indira Prithika¹,Viswanathan Balasubramaniam²,Sivasankaran Ponnusankar¹^ORCID

Affiliation:

1. Department of Pharmacy Practice JSS College of Pharmacy, JSS Academy of Higher Education & Research Ooty Tamil Nadu India

2. Department of Surgery Government Medical College and Hospital Ooty Tamil Nadu India

Publisher

Wiley

Subject

Nephrology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/nep.14011

Reference80 articles.

1. Centers for Disease Control and Prevention.Chronic Kidney Disease in the United States 2019 Chronic Kidney Dis. United States;2019.https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html. Accessed June 16 2020.

2. Chronic kidney disease (CKD)—symptoms causes treatment. National Kidney Foundation; n.d.https://www.kidney.org/atoz/content/about-chronic-kidney-disease. Accessed June 16 2020.

3. The global burden of kidney disease and the sustainable development goals

4. Preserving Kidney Function Instead of Replacing It

5. FDA.Renvela (Sevelamer carbonate) label FDA.https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022127s011lbl.pdf. Accessed June 16 2020.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of SGLT2 Inhibitors on Renal Function in Type 2 Diabetic Patients with Coronary Artery Disease Undergoing Percutaneous Intervention: A Systematic Review and Meta-Analysis;Current Diabetes Reviews;2024-07-03

2. Hyperphosphatemia in Chronic Kidney Disease: The Search for New Treatment Paradigms and the Role of Tenapanor;International Journal of Nephrology and Renovascular Disease;2024-05

3. Sevelamer Use and Mortality in People with Chronic Kidney Disease Stages 4 and 5 Not on Dialysis;Journal of Clinical Medicine;2023-12-12

4. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure;Expert Opinion on Pharmacotherapy;2023-08-11

5. Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients;Renal Failure;2023-06-05